# Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Study · id `cardio:ct-nct05041010` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05041010](<https://clinicaltrials.gov/study/NCT05041010>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05041010

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 496 participants.

## Technical summary

Registry record NCT05041010. Randomized; triple masking; primary purpose treatment. Start 2021-12-25 (actual); primary completion 2024-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 496 participants (planned count; ClinicalTrials.gov record NCT05041010, source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)
- Started: 2021-12-25 (actual) (ClinicalTrials.gov record NCT05041010, source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)
- Primary completion: 2024-06 (anticipated) (ClinicalTrials.gov record NCT05041010, source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)
- Completion: 2025-01 (anticipated) (ClinicalTrials.gov record NCT05041010, source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05041010, source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05041010-2022-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
- Acronym: RODIN
- Condition: Ischemic Stroke
- Intervention (Drug): Neu2000KWL group
- Intervention (Drug): Placebo group
- Lead sponsor: GNT Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: GNT Pharma (`cardio:org-gnt-pharma`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Nelonemdaz and Patients With Acute Ischemic Stroke and Mechanical Reperfusion: The RODIN Randomized Clinical Trial (`cardio:pubmed-39874036`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 2e4cb0b826db3134914671eb36f8b153a8c28e6ed726732c7e80aeb8133eb1b9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
